In this article, we will look at the 15 Best Long Term Low Volatility Stocks to Invest In.On January 26, Sherry Paul, Morgan Stanley senior portfolio manager, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets and whether more volatility is expected ahead.According to her, one of the most important things that came out of Davos was going from the phrase globalization to the “new world order”, in which the former felt more like a conscious uncoupling, while the latter has a much hars ...

Core Viewpoint - Pharming Group announced that the FDA issued a Complete Response Letter (CRL) for its supplemental New Drug Application (sNDA) for Joenja® (leniolisib) as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS) [1][5] Regulatory Update - The FDA raised concerns about potential underexposure in lower weight pediatric patients and requested additional pharmacokinetic data to reassess proposed doses [2] - An issue was identified with one of the analytical methods used for production batch testing, prompting the FDA to request further data and clarification [2] - Pharming plans to address the issues outlined in the CRL and intends to request a Type A meeting with the FDA to discuss next steps for resubmission [3] Clinical Data - The sNDA submission was based on positive results from a Phase III study showing improvements in lymphadenopathy and naïve B cells over 12 weeks, indicating a correction of the immune defect in children [4] - Safety data from 8 months of treatment indicated that all treatment-emergent adverse events were mild to moderate, with no serious drug-related adverse events reported [4] Market Context - Currently, there are no approved treatments for children with APDS under the age of 12 globally, highlighting the significance of Joenja's potential impact [5] - Joenja received FDA approval for treating APDS in patients aged 12 years and older in March 2023, which remains unaffected by the recent regulatory action [3][5] Disease Overview - APDS is a rare primary immunodeficiency characterized by severe recurrent infections and immune dysregulation, affecting approximately 1 to 2 people per million worldwide [6] - The condition is caused by variants in the PIK3CD or PIK3R1 genes, leading to hyperactivity of the PI3Kδ pathway, which impairs immune cell function [6] Product Information - Leniolisib is an oral PI3Kδ inhibitor approved in several countries as the first targeted treatment for APDS in patients aged 12 years and older [7] - The drug is currently under regulatory review in multiple regions and is being evaluated in clinical trials for other primary immunodeficiencies [8]

Core Insights - Bristol Myers Squibb Company (NYSE:BMY) is identified as one of the most undervalued large-cap stocks currently available for investment [1] - Analysts have raised price targets for Bristol Myers, indicating a positive outlook for the stock driven by pipeline progress and growth potential [2][3] Analyst Ratings and Price Targets - Piper Sandler increased its price target for Bristol Myers to $66 from $62, maintaining an Overweight rating, citing undervaluation due to the upcoming loss of exclusivity for Eliquis in the US [1] - Citi analyst Geoff Meacham raised the price target to $60 from $53 with a Neutral rating, highlighting favorable conditions for the biopharma sector heading into 2026 [2] - Leerink analyst David Risinger raised the price target to $60 from $54 with an Outperform rating, anticipating significant upside potential in 2026 due to a robust pipeline [3] Company Overview - Bristol Myers Squibb is involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products globally, focusing on areas such as oncology, hematology, immunology, cardiovascular, and neuroscience [4]

Core Viewpoint - Gilead Sciences, Inc. (NASDAQ:GILD) is highlighted as one of the most profitable stocks on NASDAQ, with recent price target increases from Truist Securities and Citigroup indicating strong investor confidence in the company's future performance [1][3]. Group 1: Price Target Adjustments - Truist Securities raised its price target on Gilead Sciences to $145 from $140 while maintaining a Buy rating, citing revisions in estimates for the drug YEZTUGO and updates on upcoming launches [2]. - Citigroup also increased its price target for Gilead Sciences to $156 from $140, maintaining a Buy rating, as part of a broader Q4 preview for biopharmaceutical stocks [3]. Group 2: Company Overview - Gilead Sciences is a biopharmaceutical company focused on developing medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer [4].

Group 1 - Maze Therapeutics' Senior Vice President of Finance, Amy Bachrodt, sold 5,000 shares for approximately $227,612 on January 22, 2026, following a strong performance of the company's stock [1][2] - The company has seen a remarkable 1-year price change of 172.38%, with a significant increase of 158% in 2025 after its IPO on January 31, 2025 [4][6] - Following the transaction, Bachrodt's direct ownership decreased to 12,965 shares, representing 0.0269% of the company's outstanding shares [8] Group 2 - Maze Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for renal, cardiovascular, and metabolic diseases, including obesity [5] - The company is advancing to later clinical stages for its medicines targeting kidney and metabolic diseases, which are expected to generate significant revenue upon trial completion [9] - The stock has shown consistent gains for nine months post-IPO, but investors should be cautious of potential short-term drawdowns due to the sustained high buying power [6][7]

Key TakeawaysGeopolitical tensions are escalating as Iran's parliament speaker, Mohammad Bagher Ghalibaf, declared that Iran would treat European Union armies as "terrorist groups" in retaliation for the EU's designation of the Islamic Revolutionary Guard Corps (IRGC) as a terrorist organization.Bitcoin (BTC) has plunged below $80,000, trading around $78,500 after a 6.6% drop in 24 hours, signaling a new crisis of confidence in the cryptocurrency market.China's new home prices rose by 0.18% in January, indi ...

Atle Fund Management AB grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 6.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 78,169 shares of the biopharmaceutical company’s stock after buying an additional 5,004 shares during the period. Gilead Sciences accounts for about 3.4% of Atle Fund Management AB’s investment portfolio, making the stock its 10th biggest holding. Atle ...

Core Insights - The Chief Scientific Officer of Enliven Therapeutics sold 20,000 shares amid a significant stock price increase of 71% in January 2026 [1][5] - The transaction was valued at approximately $535,100, with the shares sold being part of a pre-arranged trading plan [2][7] Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, particularly leveraging small molecule drug design [4] - The company has a market capitalization of $1.57 billion and employs 65 people [3] Financial Performance - Enliven Therapeutics reported a net income loss of $97.21 million over the trailing twelve months [3] - The stock price increased by 26.75% over the past year as of January 20, 2026 [3] Recent Developments - The company announced positive initial data from early trials of ELVN-001, a leukemia treatment, contributing to the stock's performance [5] - Enliven aims to advance to phase three of clinical trials for ELVN-001 and is preparing to work with the FDA [6] Investor Considerations - The recent stock performance is closely tied to the progress of the leukemia treatment project, suggesting that investors should monitor FDA approval developments [8]

Core Insights - Harmony Biosciences has shown promising financial performance, but the CFO, Sandip Kapadia, sold all her direct equity ownership in January 2026, raising questions about insider sentiment [1][6]. Financial Overview - As of January 31, 2026, Harmony Biosciences' stock price was $35.52, with a market capitalization of $2.1 billion, revenue of $825.94 million, and net income of $185.68 million [4]. - The transaction involved the sale of 20,961 shares for approximately $752,800, executed at a weighted average price of $35.92 per share [2][9]. Company Profile - Harmony Biosciences is a U.S.-based biopharmaceutical company focused on therapies for rare neurological diseases, with WAKIX being a notable product for treating narcolepsy [5]. Future Outlook - The company anticipates over $1 billion in revenue from WAKIX by the end of 2026, supported by an exclusive license for the medication [7]. - Other medications in advanced development stages are projected to sustain revenue generation into 2040, with a 10% increase in 2025 [8]. Insider Trading Context - Kapadia's sale fully liquidated her direct holdings, which had previously been reduced from 72,948 shares to zero over the past year [9]. - The sale price was slightly below the market close of $36.41 on the transaction date and below the current share price of $36.62 as of January 31, 2026 [9].

Core Insights - Takeda Pharmaceutical Company Limited (NYSE:TAK) is identified as one of the best healthcare stocks to buy for 2026, despite facing challenges due to VYVANSE's loss of exclusivity [1][2] Financial Performance - For Q3 FY2025, Takeda reported a revenue of ¥3,411.2 billion, reflecting a year-over-year decline of 3.3% at constant exchange rates [2] - Core operating profit decreased by 3.4% to ¥971.6 billion, while reported operating profit increased by 1.2% to ¥422.4 billion [2] - Operating cash flow rose by 15.8% to ¥966.9 billion, and adjusted free cash flow increased by 10.1% to ¥625.9 billion, indicating strong cash flow management [2] Product Performance - Growth and launch products contributed positively, rising by 6.7% at constant exchange rates and now accounting for 52% of total revenue [1] - Key growth drivers included Entyvio (+7.4%), Livtencity (+43.6%), and Qdenga (+22.1%), which helped mitigate the impact of VYVANSE's significant decline of 45.7% [1] Upcoming Products - The company is preparing to launch three transformative medicines—Oveporexton, Rusfertide, and Zasocitinib—between late 2026 and early 2027, aiming to drive long-term growth [2] - Takeda is also accelerating late-stage programs in gastrointestinal, neuroscience, and oncology sectors [2] New Product Launch - On January 22, Takeda announced the U.S. launch of GAMMAGARD LIQUID ERC, an immunoglobulin therapy for primary immunodeficiency patients aged two and older, which can be administered without reconstitution [3] - The product features Enhanced Removal Capability to lower IgA levels and is available in various vial sizes, enhancing treatment options for patients [3] Company Overview - Takeda is a top-20 global, R&D-driven biopharmaceutical company headquartered in Japan, focusing on innovative medicines in oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines [4]